Wells Fargo analyst Stephen Baxter raised the firm’s price target on Agilon Health to $28 from $22 and keeps an Overweight rating on the shares. Commentary on 2024 expectations was better-than-feared, given the potential headwinds from proposed MA rates and risk model changes, the firm notes.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGL: